Standardized uptake values (SUV) measure a patient's response to nuclear medicine therapy. But what other markers of success are there, and do these markers and the interpretation of them vary depending on the disease being imaged? Sally Barrington, MD, works specifically on lymphoma and shares her expertise on what markers of success and criteria are critical to her in understanding patients' responses to treatment. Joining her, along with our host Ken Herrmann, MD, are Louise Emmett, MD, and Irene Buvat, PhD. The panel also discusses the role of AI tools in analyzing risk and response assessment in lymphoma. Tune in now!

Below are resources provided by Dr. Barrington:

Tool to measure the international metabolic prognostic index 'IMPI':https://petralymphoma.org/impi/

Benchmark dataset for MTV measurement: https://zenodo.org/records/11409717

For more JNM articles on this topic, see below:

Methodology for MTV described in DOI: https://jnm.snmjournals.org/content/early/2020/07/16/jnumed.119.238923

Is 18F-FDG Metabolic Tumor Volume in Lymphoma Really Happening? https://doi.org/10.2967/jnumed.123.267022

Deep learning enables TMTV estimation https://doi.org/10.2967/jnumed.120.242412

This episode is sponsored by SOFIE Biosciences: